Compositions comprising E-selectin antagonists and uses therefor
AssigneeThe University of Queensland
InventorsJean-Pierre Levesque, Ingrid Winkler
Life of this patent
Estimating the term…
Abstract
This invention discloses the use of an E-selectin antagonist and a mobilizer of hematopoietic stem cells or progenitor cells in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular relevant for prophylaxis and/or treatment of hematopoeitic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.
Claims26
A method for enhancing hematopoiesis in a subject undergoing medical treatment with an agent that targets rapidly dividing cells and/or disrupts the cell cycle, the method comprising administering concurrently to the subject a mobilizer of hematopoietic stem cells or progenitor cells and an E-selectin antagonist in an effective amount to enhance hematopoiesis.
A method for treating or preventing an immunocompromised condition in a subject, which condition results from exposure of the subject to a medical treatment that targets rapidly dividing cells and/or disrupts the cell cycle, the method comprising administering concurrently to the subject a mobilizer of hematopoietic stem cells or progenitor cells and an E-selectin antagonist in amounts effective for treatment or prevention the immunocompromised condition.
Dependencies are inferred from the claim text.